Home › Research › Cognitive tests and assessment
Association of age with clinical progression across plasma p-tau217 levels
Shi R, Choity LT, Brodman ST, Zeng X, Farinas MF, Nafash MN, Gogola A, Lopresti B et al.. medRxiv, 2026-08-10
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
STRUCTURED ABSTRACT BACKGROUND Chronological age and plasma p⍰tau217 each predicts cognitive decline, but whether their prognostic associations interact is unclear. In this study, we examined their joint associations in a memory-clinic cohort. METHODS We included 3,741 participants from the Pittsburgh ADRC, with up to 28 years of follow-up (3.0 [IQR 2.0-6.0]). The primary outcome was increase in Clinical Dementia Rating global score (CDR-GS). Secondary outcomes included clinical-stage progression and longitudinal change in CDR Sum of Boxes. Plasma p-tau217 cut-off value was derived and externally validated in amyloid-beta-PET and autopsy sub-cohorts, respectively. Cox proportional hazards and linear mixed-effects models tested age-by-p-tau217 interactions while repeated cross-validation evaluated prognostic performance. RESULTS Age and plasma p-tau217 interacted in their associations with CDR-GS progression (χ(1) 2 =23.94; p=9.81×10 -7 ). Comparing the oldest displayed age with the youngest reference age, the adjusted hazard ratio was 4.80 (95% CI 2.74-8.27) in the lowest vs. 1.05 (95% CI 0.69-1.47) in the highest p-tau217 quartile. Older age was associated with clinical progression at low-p-tau217 (HR=1.97; 95% CI 1.58-2.45) but not at high-p-tau217 (HR=1.10; 95% CI 0.95-1.26) concentrations; adjusted 5-year risk differences were 19.3 and 3.3 percentage points, respectively. Adding plasma p-tau217 improved 5-year discrimination most accurately among participants younger than 60 years (AUC 0.66-0.81). DISCUSSION Prognostic association between age and clinical progression varies by plasma p-tau217 concentration. Age stratifies risk at low plasma p-tau217 levels, whereas elevated p-tau217 identifies higher risk across age groups and attenuates the age-related gradient. These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shi, R., Choity, L. T., Brodman, S. T., Zeng, X., Farinas, M. F., Nafash, M. N., et al. (2026). Association of age with clinical progression across plasma p-tau217 levels. medRxiv. https://doi.org/10.64898/2026.08.08.26359816
Vancouver
Shi R, Choity LT, Brodman ST, Zeng X, Farinas MF, Nafash MN, et al. Association of age with clinical progression across plasma p-tau217 levels. medRxiv. 2026. doi:10.64898/2026.08.08.26359816.
BibTeX
@article{shi2026-540a9f49,
author = {Shi, R. and Choity, L. T. and Brodman, S. T. and Zeng, X. and Farinas, M. F. and Nafash, M. N. and Gogola, A. and Lopresti, B. and others},
title = {{Association of age with clinical progression across plasma p-tau217 levels}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.08.08.26359816},
url = {https://doi.org/10.64898/2026.08.08.26359816}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- RESULTS Age and plasma p-tau217 interacted in their associations with CDR-GS progression (χ(1) 2 =23.94; p=9.81×10 -7 ).
- Older age was associated with clinical progression at low-p-tau217 (HR=1.97; 95% CI 1.58-2.45) but not at high-p-tau217 (HR=1.10; 95% CI 0.95-1.26) concentrations; adjusted 5-year risk differences were 19.3 and 3.3 percentage points, respectively.
- Age stratifies risk at low plasma p-tau217 levels, whereas elevated p-tau217 identifies higher risk across age groups and attenuates the age-related gradient.
- These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.
Study details
- Study designlongitudinal study
- Participants3,741
- Effect sizeHR=1.97; HR=1.10; AUC 0.66-0.81
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 50 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 31 of the 62 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,741 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 31 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 31 of the 62 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.